TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT05718453

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Tests
Description: Measurement of serum level of CRP, tumor necrosis factor, zinc, copper, potassium, sodium, and magnesium in patients with stable COPD and during exacerbation.
Study: NCT02637284

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Phase 1 a: Healthy volunteers will take a single dose of 1, 3 or 6 tablets by mouth of PCO-03 (placebo) as a control group.~Phase 1b: All subjects will take 3 tablets of PCO-03 (placebo) every 8 hours during two weeks, as a control group.
Study: NCT01832649

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Exercise
Description: Supervised moderate-vigorous exercise in group, based on strength and calisthenics exercises, 2 times per week during 8 weeks.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Health education
Description: Supervised groups 2 times per week during 8 weeks.
Study: NCT01619982

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cefazolin 25 mg/kg body weight and Vancomycin hydrochloride
Description: Cefazolin 25 mg/kg/dose administered intravenously over 5 minutes within 60 minutes of surgical incision and then re-dosed (25 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery and Vancomycin 15 mg/kg (max 1.5 gram/dose) will be administered intravenously over 1-2 hours (after completion of cefazolin infusion) For patients younger than 1 month of age, a one-time repeat dose of 15 mg/kg can be given intraoperatively 12 hours after the beginning of the first vancomycin dose if the procedure is \> 12 hours in duration. For patients equal to or older than 1 month, a one-time repeat dose of 15 mg/kg (max 1.5 grams) will be given intra-operatively 8 hours after the beginning of the first vancomycin dose if the procedure is \> 8 hours in duration.

Intervention type: DRUG
Group type: OTHER
Intervention: Cefazolin 30 mg/kg body weight
Description: Intervention: Drug: Cefazolin pre-operative prophylaxis~Other Names:~Cefazolin: Brand Names Ancef, Kefzol~Cefazolin 30 mg/kg/dose administered intravenously over 10 minutes within 60 minutes of surgical incision and then re-dosed (30 mg/kg: maximum 2 grams/dose) every 4 hours intra-operatively depending on the duration of surgery as per standard peri-operative prophylaxis for cardiac surgery.
Study: NCT03275454

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIVV009 6.5 grams
Description: Participants who weigh less than 75 kilogram (kg) will receive fixed doses of 6.5 grams of BIVV009.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIVV009 7.5 grams
Description: Participants who weigh 75 kg or more will receive fixed doses of 7.5 grams of BIVV009.
Study: NCT03432702

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Horizontal ridge augmentation
Description: Surgical procedures performed to provide the alveolar ridge with enough width and height to allow for the prosthetically driven implant placement.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Horizontal ridge augmentation
Description: Surgical procedures performed to provide the alveolar ridge with enough width and height to allow for the prosthetically driven implant placement.
Study: NCT00952978

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10 mg ilaprazole
Description: Two 5-mg ilaprazole tablets(Livzon Pharm Group Inc., China) together with one placebo capsule in a package being taken orally each morning on an empty stomach for 4 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 20 mg omeprazole
Description: One 20-mg omeprazole capsule (AstraZeneca, Losec) together with two placebo tablets in a package being taken orally each morning on an empty stomach for 4 weeks
Study: NCT02649465

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tofogliflozin
Description: The group receiving Tofogliflozin (at a dose of 20mg once daily) for 48 weeks

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Description: Sulfonylurea dosage (Glimepiride): dosing from 0.5 mg for initial 4 weeks. Then, if there is no adverse effect or no improvement of glucose metabolism, glimepiride is escalated to 6 mg once daily.
Study: NCT04023435

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PNE edcuation
Description: The PNE session will last 30 minutes and will be delivered in a one-on-one educational format with a clinician using prepared images, drawings and metaphors. The 30-minute PNE session was chosen to reflect a clinically meaningful intervention in a typical allocated time frame in clinical practice. The content of the PNE is described in detail elsewhere, using a metaphors to explain various aspects of pain including sensitization of the peripheral and central nervous system (sensitive alarm system metaphor); spreading pain (nosy neighbors metaphor); increases problems with focus and concentration (brain meeting metaphor) and difficulty with fatigue and sleep (lion metaphor).
Study: NCT00768157

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: antiviral treatment (lamivudine or entecavir)
Description: antiviral treatment (lamivudine 100mg per day or entecavir 0.5mg per day)
Study: NCT05718453

Intervention type: COMBINATION_PRODUCT
Group type: ACTIVE_COMPARATOR
Intervention: Laboratory Tests
Description: Measurement of serum level of CRP, tumor necrosis factor, zinc, copper, potassium, sodium, and magnesium in patients with stable COPD and during exacerbation.

Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Laboratory Tests
Description: Measurement of serum level of CRP, tumor necrosis factor, zinc, copper, potassium, sodium, and magnesium in patients with stable COPD and during exacerbation.
Study: NCT03068936

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Intensity modulated radiotherapy
Description: Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)

Intervention type: RADIATION
Group type: OTHER
Intervention: Intensity modulated radiotherapy
Description: Intensity modulated radiotherapy once a day, 5 times a week, continuous treatment for about 6 weeks (DT 70Gy)
Study: NCT00924612

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (containing 300 mg T)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (containing 300 mg T)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (containing 300 mg T)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (containing 300 mg T)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral testosterone undecanoate (containing 300 mg T)
Study: NCT00135330

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: exenatide
Description: subcutaneous injection, 5mcg or 10mcg, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: oral tablet, 2mg or 4mg, twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: rosiglitazone
Description: oral tablet, 2mg or 4mg, twice a day
Study: NCT04380909

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Internet-based self-help
Description: Six cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of psychological distress due to the Covid-19 situation.

Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Internet-based self-help after 3 weeks
Description: Six cognitive-behavioral, mindfulness and acceptance commitment based modules focusing on different aspects of psychological distress due to the Covid-19 situation.
Study: NCT04920071

Intervention type: DEVICE
Intervention: Visual acuity and contrast sensitivity measurement
Description: Those subjects who meet the inclusion criteria will undergo the study tests. These measurements will be performed on one eye only. Visual acuity will be quantified using two forms of the MAC chart (MAC 1 and 2) and two forms of a conventional letter design chart (C1 and 2). Contrast sensitivity will be measured using the two forms of the Pelli-Robson chart (CS1 and CS2). The order with which the test charts will be presented, in addition to the charts used (i.e. MAC 1 or 2, C1 or 2, and CS1 or 2), will be selected at random. Finally, a measurement of eye length will be collected using an IOL Master (Carl-Zeiss Meditec, USA).

Intervention type: DEVICE
Intervention: Visual acuity and contrast sensitivity measurement
Description: Those subjects who meet the inclusion criteria will undergo the study tests. These measurements will be performed on one eye only. Visual acuity will be quantified using two forms of the MAC chart (MAC 1 and 2) and two forms of a conventional letter design chart (C1 and 2). Contrast sensitivity will be measured using the two forms of the Pelli-Robson chart (CS1 and CS2). The order with which the test charts will be presented, in addition to the charts used (i.e. MAC 1 or 2, C1 or 2, and CS1 or 2), will be selected at random. Finally, a measurement of eye length will be collected using an IOL Master (Carl-Zeiss Meditec, USA).

Intervention type: DEVICE
Intervention: Visual acuity and contrast sensitivity measurement
Description: Those subjects who meet the inclusion criteria will undergo the study tests. These measurements will be performed on one eye only. Visual acuity will be quantified using two forms of the MAC chart (MAC 1 and 2) and two forms of a conventional letter design chart (C1 and 2). Contrast sensitivity will be measured using the two forms of the Pelli-Robson chart (CS1 and CS2). The order with which the test charts will be presented, in addition to the charts used (i.e. MAC 1 or 2, C1 or 2, and CS1 or 2), will be selected at random. Finally, a measurement of eye length will be collected using an IOL Master (Carl-Zeiss Meditec, USA).
Study: NCT04333108

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Masitinib
Description: Masitinib 6 mg/kg/day

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Matching placebo

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Best Supportive Care
Description: Optimal concomitant symptomatic treatments. Includes: H1- and H2-antihistamines, proton pump inhibitors (PPI), sodium cromoglycate, antidepressants, leukotriene antagonists and corticosteroids.
Study: NCT04920071

Intervention type: DEVICE
Intervention: Visual acuity and contrast sensitivity measurement
Description: Those subjects who meet the inclusion criteria will undergo the study tests. These measurements will be performed on one eye only. Visual acuity will be quantified using two forms of the MAC chart (MAC 1 and 2) and two forms of a conventional letter design chart (C1 and 2). Contrast sensitivity will be measured using the two forms of the Pelli-Robson chart (CS1 and CS2). The order with which the test charts will be presented, in addition to the charts used (i.e. MAC 1 or 2, C1 or 2, and CS1 or 2), will be selected at random. Finally, a measurement of eye length will be collected using an IOL Master (Carl-Zeiss Meditec, USA).

Intervention type: DEVICE
Intervention: Visual acuity and contrast sensitivity measurement
Description: Those subjects who meet the inclusion criteria will undergo the study tests. These measurements will be performed on one eye only. Visual acuity will be quantified using two forms of the MAC chart (MAC 1 and 2) and two forms of a conventional letter design chart (C1 and 2). Contrast sensitivity will be measured using the two forms of the Pelli-Robson chart (CS1 and CS2). The order with which the test charts will be presented, in addition to the charts used (i.e. MAC 1 or 2, C1 or 2, and CS1 or 2), will be selected at random. Finally, a measurement of eye length will be collected using an IOL Master (Carl-Zeiss Meditec, USA).
Study: NCT03068936

Intervention type: DRUG
Group type: OTHER
Intervention: Cisplatin
Description: Synchronous cisplatin (100mg / m2 / times) chemotherapy, once every 3 weeks, a total of 2 times
Study: NCT03807778

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobocertinib
Description: Mobocertinib capsule.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mobocertinib
Description: Mobocertinib capsule.
Study: NCT02212366

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active TDCS
Description: Active Stimulation
Study: NCT01983878

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ramucirumab
Description: Administered IV
Study: NCT00241449

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fulvestrant
Description: intramuscular injection 250 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tamoxifen
Description: 20 mg oral tablet
Study: NCT02109744

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Decitabine
Study: NCT02212366

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: Sham TDCS
Description: Sham Stimulation
Study: NCT02082444

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Skipping lunch
Study: NCT02048358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2B3-201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2B3-201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2B3-201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2B3-201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2B3-201
Study: NCT03879928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single ascending doses of FM101
Description: The study drug (FM101 and placebo comparator) will be administered orally as SAD doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single ascending doses of FM101
Description: The study drug (FM101 and placebo comparator) will be administered orally as SAD doses
Study: NCT02048358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2B3-201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2B3-201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2B3-201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 2B3-201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Study: NCT03879928

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single ascending doses of FM101
Description: The study drug (FM101 and placebo comparator) will be administered orally as SAD doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single ascending doses of FM101
Description: The study drug (FM101 and placebo comparator) will be administered orally as SAD doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single ascending doses of FM101
Description: The study drug (FM101 and placebo comparator) will be administered orally as SAD doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Single ascending doses of FM101
Description: The study drug (FM101 and placebo comparator) will be administered orally as SAD doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Single ascending doses of FM101
Description: The study drug (FM101 and placebo comparator) will be administered orally as SAD doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple ascending doses of FM101
Description: The study drug (FM101 and placebo comparator) will be administered orally as MAD doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple ascending doses of FM101
Description: The study drug (FM101 and placebo comparator) will be administered orally as MAD doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multiple ascending doses of FM101
Description: The study drug (FM101 and placebo comparator) will be administered orally as MAD doses

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Multiple ascending doses of FM101
Description: The study drug (FM101 and placebo comparator) will be administered orally as MAD doses

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Food effects of FM101
Description: The study drug (FM101) will be administered orally under fasted condition and fed condition.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Food effects of FM101
Description: The study drug (FM101) will be administered orally under fasted condition and fed condition.
Study: NCT04434547

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: PRP
Description: During the mock embryo transfer on oocyte retrieval day, 1ml of PRP was infused inside the uterus
Study: NCT02933879

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NVXT topical
Description: topical treatment

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Vehicle) Topical
Description: Placebo (Vehicle) Topical
Study: NCT03371576

Intervention type: DEVICE
Intervention: intraocular lenses
Study: NCT02048358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone hemisuccinate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone hemisuccinate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone hemisuccinate

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methylprednisolone hemisuccinate
Study: NCT02969967

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: SaeboFlex
Description: Use of the SaeboFlex orthosis for a set protocol of grasp-release activities for 50 minutes at least 3 times per week, followed by 10 minutes of grasp-release activities without the orthosis for 8 weeks. Will occur in participants' homes after discharge from inpatient rehabilitation with visit from principal investigator to progress program for 1 hour 3 times a week for the first 2 weeks and then once a week for 6 weeks.
Study: NCT04122586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tongxieyaofang(granule)
Description: Take this granule twice a day,one bag for each time,one hour after a meal,for 4 weeks
Study: NCT02566616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ulnar Nerve Stimulation
Description: 1 hour of continued stimulation of the ulnar nerve using a hand held stimulator

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Ulnar Nerve Stimulation
Description: 1 hour of continued stimulation of the ulnar nerve using a hand held stimulator
Study: NCT03490019

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: 500, 850 or 1000 mg depending on body weight once daily for 24 weeks
Study: NCT03747536

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Description: ipratropium bromide via metered dose spray (21 micrograms per spray)

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: normal saline delivered via metered dose spray
Study: NCT02529670

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Laser
Description: Low level laser therapy will be delivered through Laser Photon III ® (DMC) in the second lumbar dorsal root ganglion.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Drug: Lidocaine
Description: 1 mL of Lidocaine will be delivered in the second lumbar dorsal root ganglion through fluoroscopy.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Radiofrequency
Description: Radiofrequency will be delivered during 300 seconds, 42oC in the second lumbar dorsal root ganglion.
Study: NCT00297128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Capecitabine
Description: 825 mg/m2 bid (on each therapy day of first 4 therapy weeks)

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cetuximab
Description: 400mg/m2 week 1, 250mg/m2 week 2-4
Study: NCT01391338

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: Oral

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ASP3652
Description: Oral

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral
Study: NCT00791804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AeroLEF
Description: Inhaled AeroLEF (Liposome-Encapsulated Fentanyl 500 mcg/mL)~* for nebulized administration as required by the patient.~* Up to a 6 mL volume (2 x 3 mL doses) containing 500 mcg/ml fentanyl.
Study: NCT01160861

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEMP1972A
Description: Repeating ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEMP1972A
Description: Repeating ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEMP1972A
Description: Repeating ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Repeating ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Repeating ascending dose

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo
Description: Repeating ascending dose
Study: NCT01531361

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Crizotinib
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib Tosylate
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Given PO

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vemurafenib
Description: Given PO
Study: NCT01027572

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Implantable neurostimulation system (Medtronic)
Description: Thalamic stimulation will be performed using an implantable neurostimulation system
Study: NCT04411706

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sintilimab Combined With Apatinib and Capecitabine
Description: Drug: Sintilimab 200mg (3mg/kg for underweight patients) intravenously, every 21 days for a cycle;~Drug: Apatinib,250mg po qd, for continuous medication;~Drug: Capecitabine,1000mg/m2 po bid, d1-d14, every 21 days for a cycle;